All Oncology News

The incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice.

Thanks to advances in research, targeted therapies, and a more personalized approach to treating patients diagnosed with breast cancer, more surgical options exist for patients with breast cancer patients than ever before.

A new study suggests that reducing physician burnout requires an organizational-level response that focuses on creating of a medical practice culture that value qualities such as teamwork, open communication, and process improvement.

Avapritinib demonstrated encouraging clinical activity in Chinese patients with PDGFRA D842V–mutant gastrointestinal stromal in a bridging study of the NAVIGATOR trial.

The novel PI3Kß inhibitor GSK2636771 plus paclitaxel led to encouraging clinical activity as well as a tolerable safety profile in patients with PTEN-deficient advanced gastric cancer who progressed following frontline chemotherapy.

This coalition of clinical research sites will partner with Genentech to advance the representation of diverse patient populations in the company’s oncology clinical trials.

The optimal sequence of therapies in the second- or later-line settings for patients with hepatocellular carcinoma remains unclear.

A new study led by Yale Cancer Center scientists revealed the combination of ATR and PARP inhibitor therapies can effectively target the enzyme isocitrate dehydrogenase-I/2 (IDH-1/2) in mutant cancer cells.

An independent data monitoring committee has recommended that the phase 3 ARMADA 200 trial examining devimistat plus high-dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia continue as planned.

Single-agent pemigatinib is being compared with gemcitabine plus cisplatin in patients with unresectable and/or metastatic cholangiocarcinoma whose tumor harbor FGFR2 fusions or rearrangements in the ongoing, phase 3 FIGHT-302 trial.

The overall picture related to COVID-19 in the Unites States is encouraging, and we might suspect that the American public would be relatively united with favorable views of efforts of public health officials and organizations at the national, state, and local levels to successfully control this terrible event and return us to our prepandemic state.

The FDA has approved FoundationOne CDx for use as a companion diagnostic for brigatinib, which was approved for the treatment of adult patients with ALK-positive, metastatic non–small cell lung cancer.

Lenvatinib can continue to be administered in patients with unresectable hepatocellular carcinoma that has Child-Pugh class B liver function, as they experienced a similar tumor size reduction as their Child-Pugh class A counterparts in a post-hoc analysis of the phase 3 REFLECT trial.

The FDA has approved a labeling supplement to the US prescribing information for neratinib that includes the dose-escalated use of the agent in patients with HER2-positive breast cancer, as examined in the phase 2 CONTROL trial, and the new 133-count commercial Nerlynx SKU.

Frontline pembrolizumab plus lenvatinib, and chemotherapy is being tested against chemotherapy alone in patients with advanced gastroesophageal adenocarcinoma, as part of the international, 2-part, phase 3 LEAP-015 trial.

The FDA has accepted the filing of the new drug application for surufatinib as a potential therapeutic option for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Enrollment to the pivotal phase 3 MOMENTUM trial, which is evaluating the novel JAK1/2 and ACVR1/ALK2 inhibitor momelotinib vs danazol in patients with symptomatic myelofibrosis and anemia, has completed.

Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting

The combination of adagrasib and cetuximab is being investigated in patients with previously treated, advanced, KRAS G12C–mutant colorectal cancer in the international, phase 3 KRYSTAL-10 study.

The FDA has approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as part of a chemotherapy regimen to treat pediatric and adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products.

Eunice Wang, MD, discusses the KOMET-001 trial, the potential for KO-539 to address an unmet need in acute myeloid leukemia, and the future of menin inhibition in this disease.

Lenvatinib demonstrated superiority to sorafenib in the first-line setting for patients with unresectable hepatocellular carcinoma, according to results of a propensity score matching analysis.

David P. Mason, MD, discusses new neoadjuvant and adjuvant developments in the treatment of patients with non–small cell lung cancer, as well as what those data mean from a surgical perspective.

The fixed combination of daunorubicin and cytarabine continued to demonstrate improved overall survival vs 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System.

Early detection of primary lung cancer using low-dose computed tomography screening was associated with a lower risk of brain metastases after PLC diagnosis vs other methods

The debate continues as to how to define oligometastatic disease and whether it represents a unique stage between limited-stage and widely metastatic disease.

Barbara Burtness, MD, has been appointed Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center.

NRG1 fusions, which are often first detected by RNA-based sequencing, confer a more molecularly, pathologically, and clinically diverse subtype of lung cancer compared with historical hypotheses.

The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike.